CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 286 enrolled
Drug / intervention
T1225 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01155999
NCT01155999Phase 3Completed
CompareCT.gov

Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.

Laboratoires Thea·interventional·Posted Jul 2, 2010·Updated Oct 29, 2014

In Brief

A Phase 3 clinical trial evaluating T1225 and Tobramycin for Purulent Bacterial Conjunctivitis. Completed, enrolled 286 participants across 1 site.

Detailed Summary

Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPurulent Bacterial Conjunctivitis
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2, 2010
Enrollment StartDec 1, 2008
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 16 years ago

Interventions

T1225drug

one drop twice daily (morning and evening) in each eye from Day 0 to Day 2

Tobramycindrug

1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6